Floatz logo

nnc0194-0499

Obesity Disorder

Novo Nordisk A/SPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity Disorder cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB
Tirzepatide
Royal North Shore Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

nnc0194-0499 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
64 / 100
View asset →
metabolic diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →